Avacta pauses sales of COVID-19 antigen test to improve Omicron sensitivity
Reuters
Published Jan 10, 2022 03:24AM ET
Updated Jan 10, 2022 05:00AM ET
By Amna Karimi and Pushkala Aripaka
(Reuters) -Britain's Avacta Group is halting sales of its COVID-19 rapid antigen lateral flow test to replace antibodies in the device and boost its ability to detect the Omicron variant, the biotech firm said on Monday, sending its shares plunging nearly 27%.
The London-listed company's test, AffiDX, can detect the Omicron variant when the virus is present in high numbers in samples, but tests carried out by Avacta found AffiDX is less sensitive to Omicron at lower viral loads versus other variants.
Scientists and governments are scrambling to bolster defences against Omicron with testing, shots, therapies, and by decoding the viral genomes to try and measure how far it has spread as the variant threatens to become dominant globally.
"Our determination to only provide ... high performance diagnostic tests has led us to the ... decision to pause all marketing of the AffiDX lateral flow antigen test," Avacta CEO Alastair Smith said, urging others to also assess the sensitivity of their products to Omicron.
Experts and health authorities have warned https://www.reuters.com/business/healthcare-pharmaceuticals/rapid-nose-swab-tests-covid-may-not-detect-omicron-quickly-enough-expert-says-2022-01-07 that COVID-19 rapid antigen tests - which rely on nose swabs - may not detect Omicron quickly enough since people can transmit it in early stages of the infection before the virus reaches their nose.
The tests are popular for home and travel checkpoints for their quick results and cheaper prices compared with other elaborate tests.
While Avacta did not say when it expects to resume sales of an AffiDX test better-suited to Omicron, it said COVID-19 testing "remains a long-term commercial opportunity" for the company.
Shares in the company slid 26.5% to 85.25 pence in morning trade in London, erasing the roughly 11% gains it recorded in 2021.
Avacta and other test makers also had to pull some of their COVID-19 tests from the British market after a new review system came into force, which has not yet granted approval for their previously accepted products.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.